chrisvoncsefalvay/vaers-outcomes huggingface dataset:
60 days since first dose; This spontaneous case was reported by a health care professional and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (60 days since first dose) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (60 days since first dose). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (60 days since first dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications have been reported.  The patient had travel arrangements, which interfered with receiving the second dose.  No treatment information was provided.
Mil headache, muscle joint pain and Vertigo like symptoms that have lasted 1 week so far. The dizziness is coupled with nausea depending on my activity. I was unable to do much at all because of the severity of this. I will not take another vaccine no matter what. Being this sick is ridiculous, I will take my chances.
ADMINISTRATION OF TWO DOSES OF JNJ VACCINE; This spontaneous report received from a health care professional concerned a female of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 203A21A expiry: UNKNOWN, and batch number: 1816027 expiry: UNKNOWN) dose was not reported, administered on 01-JUN-2021, and dose was not reported, administered on 14-JUN-2021 for prophylactic vaccination. No concomitant medications were reported.  On 14-JUN-2021, the subject experienced administration of two doses of JNJ vaccine. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of administration of two doses of JNJ vaccine was not reported. This report was non-serious. This case, from the same reporter is linked to 20210634981.
soreness of her lymph nodes; This spontaneous case was reported by a consumer and describes the occurrence of LYMPH NODE PAIN (soreness of her lymph nodes) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031a21a) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Mar-2021, the patient experienced LYMPH NODE PAIN (soreness of her lymph nodes). At the time of the report, LYMPH NODE PAIN (soreness of her lymph nodes) had not resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Reporter did not allow further contact
Approximately 25 minutes after shot administered: A single welt/hive appeared on my right thigh approx. 6? above my knee; was warm and raised. Dissipated after 1 hour; Re-appeared around 6 pm but less irritating. Not present today. (Haven?t had any hives in more than a decade.) Roof of mouth and ear canals became very warm and itchy...like an intensifying of my seasonal allergies. Continued to decrease after 7 pm; also used a cold milkshake to relieve the sensation between 5:15 pm and 6:00 pm. Both sides of my tongue swelled and were itchy.  Symptom subsided around 7 pm. Minimal pain at injection site; no redness No fever, no headache.
RSD/ CRPS flared up, normal symptoms of that disorder.; RSD/ CRPS flared up; This is a spontaneous report from a contactable consumer, the patient. A 22-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in left arm on 30Mar2021 at 16:15 (at the age of 22-years old) as a single dose for COVID-19 immunisation. The patient also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration in left arm on 20Apr2021 at 16:15 (at the age of 22-years old) as a single dose for COVID-19 immunisation. The patient's medical history included reflex sympathetic dystrophy/ chronic regional pain syndrome. Known allergies were not reported   The patient did not receive any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 21Apr2021 at 16:00, approximately 24 hours after each dose the patient had experienced reflex sympathetic dystrophy/ chronic regional pain syndrome flared up .  The events did not result in doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of adverse events. The clinical outcome of the event, reflex sympathetic dystrophy/ chronic regional pain syndrome flared up was not recovered at the time of report.  No follow-up attempts are needed. No further information is expected.
FIRST SHOT created flu like symptoms but most noted here are the three episodes of cold sores over my lips and nose over the next month. Reason to fill out this VAERS report is to tell you that when I took my second shot (3/8/19), I took my ACYCLOVIR TABS at the same time and only developed flu like symptoms. People with a chronic problem of cold sores would really benefit from antiviral medications when getting the vaccine.
devel generalized itching p/vax 24NOV98;devel generalized hives, some SOB which subsided w/DPH;seen by MD;
Fever 101.8 F; Severe Headache; Severe Body Aches; Lethargic
About 15 min after receiving my Moderna vaccine I started to itch and got a few hives. Benedryl was taken.
Covid-19; Covid-19; This is a spontaneous report received from contactable reporter(s) (Nurse) from a sales representative. The reporter is the patient.  A 38-year-old female patient (not pregnant) received bnt162b2, bnt162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; covid-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2023, outcome "unknown" and all described as "Covid-19". Therapeutic measures were taken as a result of covid-19 included Paxlovid from 01Sep2023 to 06Sep2023.  The information on the batch/lot number for bnt162b2, bnt162b2 omi ba.4-5 has been requested and will be submitted if and when received.; Sender's Comments: Based on available information, a lack of efficacy with the suspect vaccine bnt162b2, bnt162b2 omi ba.4-5 in this patient cannot be completely excluded.
I received two doses of the covid 19 shot and now I am getting my menstrual cycle every two weeks. I am bleeding heavy and now it seems as if I have busted blood vessels all over my body. I am nauseous.
Flu like symptoms, body ache, extreme tired worn out feeling, headache, nausea.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 33-year-old male patient received BNT162b2 (BNT162B2), on 27Oct2021 at 12:00 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 32 years, in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2022, outcome "not recovered" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (13Jul2022) Negative; (14Jul2022) Negative; (16Jul2022) Positive. Therapeutic measures were taken as a result of drug ineffective, covid-19 included Paxlovid from 08Jul2022 to 12Jul2022.   Clinical Course: No Other medication in 2 weeks. COVID symptoms returned following completion of 5-day Paxlovid course. Tested positive again on 16Jul, 4 days after completing treatment testing negative on 13Jul and 14Jul.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
redness & heat to site rt deltoid 3cm x 4cm area, area very tender;
Patient was given an HPV9 injection. Fainted a few minutes later. LOC for a few seconds. She awoke when we were trying to elevate her legs.  She knew her name. Ice pack to head. No lumps. The tip of her tongue was bit. Very little blood. EMS called. EMS assessed client. Vital signs good. Mom declined transport. EMS told mom and dad to observe her at home for the next couple of days. Client left with parents.
Persistent pain in arm primarily at elbow and moving to forearm. Never had this time of issue before. Seems slightly swollen. Going to check with doctor for inflammation/bursitis.
Vaccine administered after temperature excursion; This spontaneous case was reported by an other health care professional (subsequently medically confirmed) and describes the occurrence of PRODUCT STORAGE ERROR (Vaccine administered after temperature excursion) in a 48-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003B21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 02-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Apr-2021, the patient experienced PRODUCT STORAGE ERROR (Vaccine administered after temperature excursion). At the time of the report, PRODUCT STORAGE ERROR (Vaccine administered after temperature excursion) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments.   No Concomitant Medication was provided. No Treatment medication was provided.   This case was linked to MOD21-068620 (E2B Linked Report).; Sender's Comments:  MOD21-068620:crosslinked
AFTER FIRST GARDASIL VACCINE (administered 9/13/06): experienced dizziness, light-headed, nauseous, headaches, leg cramps, and shooting leg pain.  AFTER SECOND GARDASIL VACCINE (administered 11/13/06): experienced same symptoms after first dose plus hair loss, abdominal bloating, menstrual cycle stopped, weakness, poor circulation. AFTER THIRD GARDASIL VACCINE (administered 3/13/07): experienced all symptoms listed above plus excessive hair loss, pale/purple skin, always cold, loud ringing in ears, extreme digestive problems, stomach pain, gastrointestinal discomfort, chronic constipation, joint pain, facial swelling, chronic fatigue, irritability, easily agitated, extreme weakness and all-over muscle fatigue (with difficulty in walking, talking, moving, etc.). TREATMENT: had to seek alternative medicine doctors to receive nutritional supplementation because other doctors could do nothing for me.  Recently have been referred to a clinic. (scheduled appt. for 3/30/09). 3/18/09-records received for DOS 5/18-5/20/08-DC DX: Chronic constipation. Exercise induced asthma. Cyanosis. Pancytopenia. Presented to ED with increased generalized weakness and constipation since 2/08.Taking a Chinese herbal formula for chronic fatigue astra lsatis. Possibility of viral syndrome secondary to hepatitis C. PE: differential in pulses bilaterally, cyanotic in extremities pulse ox O2 saturation 87% at exercise but increased at rest.  Follow-up: Leg pain, numbness, stiffness, partial organ failure, anemia low platelets, cardiac arrhythmia, low body temperature, EBV onset, Hep C onset, UTIs, pancreatitis, amenorrhea, melanosis coli, gout, boils, Baker's cyst, swollen glands hypothyroidism, hypoglycemia, chronic somnolence episode tachycardia, dysphagia, orthopnea, thrombocytopenia.
Patient returned to health center c/o chills; temperature was 101.2.  PE was negative; site of immunization was w/o erythema, edema, increased warmth, or rash.  Given acetaminophen 325 mg, 2 tabs po, and sent home. Stayed home on 09/18/2013 with c/o generalized body aches, fatigue, rhinorrhea, weakness, and slight dizziness. Temperature WNL after decrease to 100 in PM on 09/17/2013.  Spoke with patient on 09/19/2013; remains at home with c/o slight dizziness on rising which resolved, fatigue, and weakness. Advised to call PMD.
Lost the ability to walk, could not manage to even get on the potty placed right next to the bed; Developed a headache that remained off and on for 24 hours,  along with a fever of 100.8.; Fever of 100.8; This is a spontaneous report received from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6204), via an unspecified route of administration in the left arm on 16Mar2021 at 18:30 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history included multiple sclerosis. The patient was allergic to penicillin, sulfa drugs and avocados. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient received unspecified medications within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL9267), via an unspecified route in the right arm on 23Feb2021 at 18:15 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 17Mar2021 at 01:00, the patient developed a headache that remained off and on for 24 hours, along with a fever of 100.8. The fever was treated and broke 8 hours after its initiation, however, prior to that, she had lost her ability to walk. She could not manage to even get on the potty placed right next to her bed, although her husband was trying to lift her. The patient was treated for the event fever and the patient did not any receive any treatment for the events headache and unable to walk. The clinical outcome of the event headache was recovered on 18Mar2021 while that of fever of 100.8 and unable to walk was recovered on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
This case was reported by a physician via interactive digital media and described the occurrence of general body pain in a adult patient who received SHINGRIX. On an unknown date, the patient received SHINGRIX .5 ml. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced general body pain, fever, pain in arm, flu syndrome, diarrhea, fatigue, injection site erythema, unwell and pharmaceutical product complaint. On an unknown date, the outcome of the general body pain, fever, pain in arm, flu syndrome, diarrhea, fatigue, injection site erythema, unwell and pharmaceutical product complaint were unknown. It was unknown if the reporter considered the general body pain, fever, pain in arm, flu syndrome, diarrhea, fatigue, injection site erythema and unwell to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The physician purchased a dose of SHINGRIX and had a patient with bad side effects. The patient experienced sore arm, redness around injection site, flu syndrome, fever, fatigue, and diarrhea. The physician also posted on social media, SHINGRIX made the patient ill and he would not give SHINGRIX to another human. The physician was requesting reimbursement for these doses of SHINGRIX. The Vaccine Service Center (VSC) said that, they could only reimburse for a product complaint. His main thought was to get reimbursed. He would like to talk to someone. He was requesting to speak with the vice president of the company. He reached out to his sales representative who had not gotten back to him. The physician would like a call back to resolve this situation. The physician was not willing to provide more information about the adverse event's because he had already reported the events. This is 1 of 13 cases, reported by the same reported for the patient's who experienced adverse events after receiving SHINGRIX.
COVID Vaccine administered 12/21/20 @ 15:16 and about 15 minutes later, pt reported feeling tachycardic.  She felt short of breath and had a tingling sensation on her tongue.  25 mg of benadryl PO was given to her at 15:30.  She continued to feel SOB and her voice sounded much more compromised so an additional 25 mg of benadryl PO was given and she was taken to the ED for observation.  In the ed she was given prednisone and pepcid.
1 day after getting the booster, developed hearing loss in left ear for the morning. Later hearing returned to normal. Also had left eye redness that appeared to be conjunctivitis.
Within 24 hours of vaccine administration pt's mother measured temperature of 103.0 F aurally.
arm hurt; rash at the injection site; swelling of her arm and armpit; chills; low grade fever; headache; This is a spontaneous report from a contactable consumer (patient). A female patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for Injection, Lot number: unknown), via an unspecified route of administration on 31Aug2021 as dose 2, single for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. Historical vaccine included BNT162B2, dose 1 on an unspecified date for COVID-19 immunisation. The patient reported her arm hurt, rash at the injection site, swelling of her arm and armpit, chills, low grade fever and headache. She asked if she could take Tylenol after her second dose of the Pfizer-BioNTech COVID-19 Vaccine, yesterday (31Aug2021). The outcome of all events was unknown.
Began with burning, itching both forearms, developed large welts w/ redness and swelling, spreading to (R) hand and (R) upper arm and upper delt leg-applied cortisone 1% and took BENADRYL. 2 AM hives worsened. 6:45 AM hives receding. Additional (R) ankle and knee joint pain and swelling-took BENADRYL 3:05PM on 8/21/15.
Received swine FLUMIST, 1 hr later developed redness, itching and bruising to bilateral lower extremities. Redness and itching resolved in 1 hr, bruising persisted x 24 h, lower extremities also tender to palpation.
Raspy voice in the morning; The right side of his mouth is droopy. The droopiness is not excessive, but it is odd.; Right eyelid puffiness/ on the right side of patient's face, the eyelid was puffy; Right eye full of fluid/Under that eyelid is full of fluid; Can't hardly see out of right eye due to swelling; This is a spontaneous report from a contactable consumer. A 71-year-old male patient (reporter's husband) received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL3299) via an unspecified route of administration on the left arm on 13Jan2021 14:00 at a single dose for COVID-19 immunization at a clinic/ used empty offices. Medical history included being diabetic, had heart attacks and blood clots on unspecified dates. It was confirmed that all of this occurred years ago prior to COVID-19 vaccination. The patient had no relevant family medical history and no relevant tests. The patient takes a number of medications (unspecified). The patient previously received Flu shot at least six weeks ago in Nov2020 and had no adverse events. The patient had no additional vaccines administered on the same date as BNT162B2. The reporter and her husband (patient) got their shots on Wednesday afternoon. That morning, on 15Jan2021 at 08:00, on the right side of patient's face, the eyelid was puffy/ right eyelid puffiness. He can hardly see out of it. He can see. Under that eyelid was full of fluid/ right eye full of fluid. The right side of his mouth was droopy. The droopiness was not excessive, but it was odd. The reporter also stated that the "patient had a raspy voice in the morning anyways." The outcome of the events was unknown.
Patient with history of vasovagal syncope with vaccination. Vaccine administered with patient in Semi-Fowler's position. Patient maintained position for 15 minutes. Patient left clinic with mother, sister and brother after denying dizziness and stating she "felt fine". Mother reported after patient was seated in car, she fainted. Time was approximately 5:50. Patient's sister immediately came to clinic for documenting provider to respond. Patient was conscious, alert and oriented x3. BP 102/60, Pulse 62, Respirations 15, O2 sats 99%, Temperature 97.6 Deg F. After 10 minutes, when patient stated she felt better, patient's mother said they were going home. Reviewed signs of severe allergic reaction with parent with instructions to call 911 if she thinks it is a severe allergic reaction. Mother verbalized understanding. A follow up call to mother was made at 7:30 PM and mother reported patient was doing well.
PAIN ON  THE LEFT ARM WHERE HE GOT THE INJECTION; This spontaneous report received from a patient concerned a 73-year-old male. The patient's height, and weight were not reported. The patient did not have known drug allergies. The patient previously received covid-19 vaccine ad26.cov2.s (dose number in series 1) (suspension for injection, route of admin not reported, batch number: 1805029, and expiry: UNKNOWN) dose was not reported, 1 total, administered on 18-MAR-2021 for prophylactic vaccination at left arm. On 18-MAR-2021, the patient experienced pain on the left arm at site of injection for 2 to 3 hours (dose number in series 1). The patient recovered from pain on the left arm at site of injection. The patient received booster covid-19 vaccine ad26.cov2.s (dose number in series 2) (suspension for injection, route of admin not reported, batch number: 213D21A, and expiry: UNKNOWN) dose was not reported, 1 total, administered on 11-NOV-2021 for prophylactic vaccination at left arm. No concomitant medications were reported.  On 11-NOV-2021, the patient experienced pain on the left arm where he got the injection (dose number in series 2). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from pain on the left arm where he got the injection on 14-NOV-2021. This report was non-serious. This case, involving the same patient is linked to 20220222828.
Patient experienced intense pain, arm was a deep red color, hard and area was raised with other small lesions around the main area. Area took up majority of patient's upper arm.  SkinRash, Rash & Edema, pain  DIPHENHYDRAMINE 50 MG ONCE
woke up at 6:00 am with a hot face, I had swollen cheeks that were bright red. the rash was very itchy. The rash didn?t fully subside until 6pm.